Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN PF 10 versus AMINOSYN RF 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN PF 10 versus AMINOSYN RF 5 2.
AMINOSYN-PF 10% vs AMINOSYN-RF 5.2%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-PF 10% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in neonates and pediatric patients.
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
Intravenous infusion: 1-1.5 g amino acids/kg/day (protein equivalent) as part of total parenteral nutrition. Typical rate: 0.5-2.0 mL/kg/hour initially, titrated to metabolic needs.
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 mL to 1000 mL/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
None Documented
None Documented
Variable; amino acids have half-lives of minutes to hours; clinical context: continuous infusion maintains steady state
The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes.
Renal: >90% as amino acids and metabolites; <10% fecal/biliary
Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution